AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27169837 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg quercetin‐3‐O‐glucoside
Number of subjects: 15
Study 27169837 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg quercetin‐3‐O‐glucoside
Number of subjects: 15
Study 27169837 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg quercetin‐3‐O‐glucoside
Number of subjects: 15
Study 27169837 — intervention group
Group type: COMPARATOR
Intervention: 0 mg quercetin‐3‐O‐glucoside (control)
Number of subjects: 15
Study 24280722 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublobar resection
Number of subjects: 347
Study 24280722 — intervention group
Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 347
Study 24280722 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublobar resection (for tumors 20 mm or less)
Number of subjects: 347
Study 24280722 — intervention group
Group type: COMPARATOR
Intervention: Lobectomy (for tumors 20 mm or less)
Number of subjects: 347
Study 21792687 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar radiofrequency tonsillotomy
Number of subjects: 26
Study 21792687 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser tonsillotomy
Number of subjects: 26
Study 21792687 — intervention group
Group type: COMPARATOR
Intervention: Both methods (radiofrequency and laser tonsillotomy)
Number of subjects: 26
Study 21792687 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency tonsillotomy
Number of subjects: 26
Study 21049059 — intervention group
Group type: EXPERIMENTAL
Intervention: Paromomycin (PM) at 15 mg/kg/day for 21 days
Number of subjects: 135
Study 21049059 — intervention group
Group type: COMPARATOR
Intervention: Sodium stibogluconate (SSG) at 20 mg/kg/day for 30 days
Number of subjects: 135
Study 21049059 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PM and SSG
Number of subjects: 135
Study 18990781 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Number of subjects: 85000
Study 18990781 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaccine
Number of subjects: 85000
Study 15756061 — intervention group
Group type: EXPERIMENTAL
Intervention: Thick loop TURP
Number of subjects: 103
Study 15756061 — intervention group
Group type: COMPARATOR
Intervention: Standard loop TURP
Number of subjects: 103
Study 11788911 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin, fluorouracil (5‐FU), l‐leucovorin and interferon alpha2b (PFL‐IFN)
Number of subjects: 26
Study 11788911 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiotherapy with 5‐FU, hydroxyurea and radiation (FHX)
Number of subjects: 26
Study 11788911 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival and progression-free survival
Number of subjects: 26
Study 11788911 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicity assessment
Number of subjects: 26
Study 10438259 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (1200 mg per day)
Number of subjects: 2531
Study 10438259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2531
Study 7586435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent antegrade warm blood cardioplegia
Number of subjects: 720
Study 2147914 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg ticlopidine twice daily
Number of subjects: 296
Study 2147914 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg aspirin every third day plus 75 mg dipyridamole three times daily
Number of subjects: 296
Study 2147914 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg xanthinol nicotinate three times daily
Number of subjects: 296
Study 6996932 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg dipyrone
Number of subjects: 267
Study 6996932 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg aspirin
Number of subjects: 267
Study 6996932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 31116404 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's Healthy Living (CHL) intervention
Number of subjects: 0
Study 31083151 — intervention group
Group type: EXPERIMENTAL
Intervention: Guardix-SG
Number of subjects: 214
Study 31083151 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 214
Study 29036255 — intervention group
Group type: EXPERIMENTAL
Intervention: tavaborole 5% solution
Number of subjects: 84
Study 29036255 — intervention group
Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 84
Study 26520398 — intervention group
Group type: EXPERIMENTAL
Intervention: RT combined with NMES (RT + ES)
Number of subjects: 39
Study 26520398 — intervention group
Group type: COMPARATOR
Intervention: RT with sham stimulation (RT + Sham)
Number of subjects: 39
Study 23410889 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA85A vaccine
Number of subjects: 2797
Study 23410889 — intervention group
Group type: COMPARATOR
Intervention: Candin control
Number of subjects: 2797
Study 22832391 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 UI of vasopressin intranasally
Number of subjects: 20
Study 22832391 — intervention group
Group type: COMPARATOR
Intervention: Placebo intranasally
Number of subjects: 20
Study 19332190 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel administration in patients with STEMI
Number of subjects: 11177
Study 19332190 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel administration in patients with non-STEMI
Number of subjects: 11177
Study 19332190 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel administration in patients with unstable angina
Number of subjects: 11177
Study 19332190 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel use in patients with non-ST elevation ACS with positive cardiac biomarkers
Number of subjects: 11177
Study 19332190 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel use in patients with non-ST elevation ACS without positive cardiac biomarkers
Number of subjects: 11177
Study 19332190 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel administration in patients <65 years old receiving fibrinolytic therapy for STEMI
Number of subjects: 11177
Study 19332190 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel administration in patients 65 to 74 years old receiving fibrinolytic therapy for STEMI
Number of subjects: 11177
Study 19332190 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel administration in patients >75 years old receiving fibrinolytic therapy for STEMI
Number of subjects: 11177
Study 17179870 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention consisting of one in-person counseling session followed by two MI telephone calls over 6 months
Number of subjects: 56
Study 17179870 — intervention group
Group type: COMPARATOR
Intervention: Control group received two telephone calls without MI content
Number of subjects: 56
Study 17179870 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention
Number of subjects: 56
Study 17179870 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 15785163 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril (angiotensin-converting enzyme inhibitor)
Number of subjects: 0
Study 15785163 — intervention group
Group type: COMPARATOR
Intervention: Contemporary therapeutic regimen (without trandolapril)
Number of subjects: 0
Study 15259398 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex (2 mg)
Number of subjects: 13
Study 15259398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 15259398 — intervention group
Group type: COMPARATOR
Intervention: Cholinesterase inhibitor (THA)
Number of subjects: 13
Study 9440036 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse neural tension assessed using the slump test
Number of subjects: 14
Study 9440036 — intervention group
Group type: COMPARATOR
Intervention: Control group (injury-free matched control group)
Number of subjects: 14
Study 9440036 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring flexibility measured using the active knee extension in lying test
Number of subjects: 14
Study 7605022 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (target concentrations of 2, 4, or 6 micrograms/ml) with alfentanil (initial target concentration 50 ng/ml)
Number of subjects: 21
Study 7605022 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (plasma concentrations increasing from 10 to 150 ng/ml)
Number of subjects: 21
Study 2398251 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 21
Study 2398251 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactitol
Number of subjects: 21
Study 2398251 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 21
Study 377119 — intervention group
Group type: EXPERIMENTAL
Intervention: Anginin
Number of subjects: 17
Study 377119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31517811 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational Emotive Occupational Health Coaching (REOHC) for 12 weeks
Number of subjects: 63
Study 31517811 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 63
Study 28428110 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 3140
Study 28428110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3140
Study 28428110 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak flow categorized as 10 to 14.9 ml/s
Number of subjects: 3140
Study 28428110 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak flow categorized as less than 10 ml/s
Number of subjects: 3140
Study 28428110 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak flow categorized as 15 or greater ml/s
Number of subjects: 3140
Study 28428110 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak flow categorized as 10 to 14.9 ml/s (multivariable analysis)
Number of subjects: 3140
Study 26168262 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Focused Therapy for Clinical High‐Risk (FFT‐CHR), an 18-session intervention consisting of psychoeducation and training in communication and problem solving.
Number of subjects: 90
Study 26168262 — intervention group
Group type: COMPARATOR
Intervention: 3-session family psychoeducational intervention (Control group).
Number of subjects: 90
Study 26168262 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (FFT-CHR and control).
Number of subjects: 90
Study 23904409 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 24
Study 23904409 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone with prednisolone
Number of subjects: 24
Study 23904409 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone (control group)
Number of subjects: 24
Study 23904409 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined glucocorticoid receptor/mineralocorticoid receptor stimulation with prednisolone
Number of subjects: 24
Study 23904409 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone with prednisolone (control group)
Number of subjects: 24
Study 21734467 — intervention group
Group type: EXPERIMENTAL
Intervention: rMenB
Number of subjects: 104
Study 21734467 — intervention group
Group type: EXPERIMENTAL
Intervention: rMenB+OMVNW
Number of subjects: 104
Study 21734467 — intervention group
Group type: COMPARATOR
Intervention: Control (licensed quadrivalent meningococcal polysaccharide vaccine and hepatitis B vaccine)
Number of subjects: 104
Study 21734467 — intervention group
Group type: EXPERIMENTAL
Intervention: rMenB and rMenB+OMVNW
Number of subjects: 104
Study 19388866 — intervention group
Group type: EXPERIMENTAL
Intervention: guaraná 75 mg daily p.o.
Number of subjects: 36
Study 19388866 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study 16626411 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ)
Number of subjects: 664
Study 16626411 — intervention group
Group type: COMPARATOR
Intervention: Fail-first algorithm on conventional antipsychotics (CON)
Number of subjects: 664
Study 16626411 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (RIS)
Number of subjects: 664
Study 16626411 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment requiring switching
Number of subjects: 664
Study 14697107 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention involving interviews with surrogates and decisionally capable older children regarding information adequacy, understanding, communication, and perceived decisional conflicts.
Number of subjects: 127
Study 14697107 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention involving tailored follow‐up recommendations based on findings relayed to the clinical team.
Number of subjects: 127
Study 10765588 — intervention group
Group type: EXPERIMENTAL
Intervention: Global recruitment strategy
Number of subjects: 0
Study 10765588 — intervention group
Group type: EXPERIMENTAL
Intervention: Three methods of recruitment
Number of subjects: 0
Study 10765588 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization of community resources
Number of subjects: 0
Study 8936399 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of caffeine in coffee
Number of subjects: 10
Study 8936399 — intervention group
Group type: EXPERIMENTAL
Intervention: shorter than 15 min nap
Number of subjects: 10
Study 8936399 — intervention group
Group type: COMPARATOR
Intervention: coffee placebo
Number of subjects: 10
Study 1984696 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 18
Study 1984696 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 18
Study 6854139 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSO (30 ml, 70% solution)
Number of subjects: 8
Study 6854139 — intervention group
Group type: COMPARATOR
Intervention: Sulindac (400 mg, orally)
Number of subjects: 8
Study 31820304 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg orodispersible tablet (DT1)
Number of subjects: 23
Study 31820304 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg oral solution (SOL)
Number of subjects: 23
Study 31820304 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg orodispersible tablet without water (DT2dry)
Number of subjects: 23
Study 31820304 — intervention group
Group type: COMPARATOR
Intervention: 10-mg orodispersible tablet with water (DT2water, reference formulation)
Number of subjects: 23
Study 31663285 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg once daily for 16 days)
Number of subjects: 390
Study 31663285 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban (10 mg once daily for 16 days)
Number of subjects: 390
Study 29023203 — intervention group
Group type: EXPERIMENTAL
Intervention: Media portrayal where mental illness was stigmatized
Number of subjects: 316
Study 29023203 — intervention group
Group type: EXPERIMENTAL
Intervention: Media portrayal where mental illness was trivialized
Number of subjects: 316
Study 29023203 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific examples of different mental illness portrayals
Number of subjects: 316
Study 26791022 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise + smoking cessation maintenance
Number of subjects: 413
Study 26791022 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise maintenance + contact control
Number of subjects: 413
Study 26791022 — intervention group
Group type: COMPARATOR
Intervention: smoking cessation maintenance + contact control
Number of subjects: 413
Study 26791022 — intervention group
Group type: COMPARATOR
Intervention: contact control
Number of subjects: 413
Study 26197999 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg elobixibat
Number of subjects: 36
Study 26197999 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg elobixibat
Number of subjects: 36
Study 26197999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 26197999 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg elobixibat
Number of subjects: 36
Study 26197999 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg elobixibat
Number of subjects: 36
Study 22560756 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 minutes tactile
Number of subjects: 20
Study 22560756 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 minutes tactile
Number of subjects: 20
Study 22560756 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 minutes nontactile
Number of subjects: 20
Study 22560756 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 minutes nontactile
Number of subjects: 20
Study 22560756 — intervention group
Group type: COMPARATOR
Intervention: Control (neutral reading)
Number of subjects: 20
Study 20232605 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling along with a home telemonitoring scale and instructions to self‐weigh daily
Number of subjects: 100
Study 18412682 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential mobility rate
Number of subjects: 585
Study 18412682 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-demographic factors
Number of subjects: 585
Study 15998777 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (0.5 g, then 0.25 g, 6 wk each)
Number of subjects: 70
Study 15998777 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone starting with 0.1 g/d, then tapering the dose by 0.01 g/wk
Number of subjects: 70
Study 15998777 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucocorticoid therapy
Number of subjects: 70
Study 15998777 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous steroids
Number of subjects: 70
Study 12776578 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine (10 mg once daily)
Number of subjects: 0
Study 12776578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12776578 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine (60 mg, twice daily)
Number of subjects: 0
Study 12776578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg once daily)
Number of subjects: 0
Study 12776578 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg once daily)
Number of subjects: 0
Study 10323778 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma tHcy
Number of subjects: 100
Study 10323778 — intervention group
Group type: COMPARATOR
Intervention: Lowest tHcy quintile
Number of subjects: 100
Study 8603453 — intervention group
Group type: EXPERIMENTAL
Intervention: ThioTEPA 30 mg/30 ml distilled water
Number of subjects: 8
Study 8603453 — intervention group
Group type: EXPERIMENTAL
Intervention: ThioTEPA 30 mg/60 ml distilled water
Number of subjects: 8
Study 8603453 — intervention group
Group type: EXPERIMENTAL
Intervention: ThioTEPA 60 mg/30 ml distilled water
Number of subjects: 8
Study 8603453 — intervention group
Group type: EXPERIMENTAL
Intervention: ThioTEPA 60 mg/60 ml distilled water
Number of subjects: 8
Study 2177347 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 142
Study 2177347 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 142
Study 54579 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin (5000 units of sodium heparin every 12 hours for 5 days)
Number of subjects: 24
Study 54579 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heparin treatment)
Number of subjects: 24
Study 54579 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin treatment
Number of subjects: 24
Study 54579 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 31493728 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0
Study 31493728 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) anticoagulants (Vitamin K antagonists or Low Molecular Weight Heparin)
Number of subjects: 0
Study 28445291 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/sevoflurane anesthesia (n=25)
Number of subjects: 50
Study 28445291 — intervention group
Group type: COMPARATOR
Intervention: Propofol-based TIVA (n=25)
Number of subjects: 50
Study 25377272 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 4
Study 25377272 — intervention group
Group type: COMPARATOR
Intervention: Control (CNI, MMF, corticosteroids)
Number of subjects: 4
Study 25377272 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI therapy after belatacept withdrawal
Number of subjects: 4
Study 25377272 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF monotherapy after belatacept withdrawal
Number of subjects: 4
Study 23646319 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid MSI
Number of subjects: 10
Study 23646319 — intervention group
Group type: COMPARATOR
Intervention: Cylindric MSI
Number of subjects: 10
Study 23646319 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MSIs
Number of subjects: 10
Study 21432821 — intervention group
Group type: EXPERIMENTAL
Intervention: Global longitudinal strain (GLS) analysis in patients with AS
Number of subjects: 44
Study 21432821 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 21432821 — intervention group
Group type: EXPERIMENTAL
Intervention: GLS in hypertrophy Groups 3 and 4
Number of subjects: 44
Study 19196206 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate cord clamping (ICC) at 5-10 seconds
Number of subjects: 65
Study 19196206 — intervention group
Group type: COMPARATOR
Intervention: Delayed cord clamping (DCC) at 30-45 seconds
Number of subjects: 65
Study 21736507 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential bilateral rTMS
Number of subjects: 74
Study 21736507 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral rTMS
Number of subjects: 74
Study 21736507 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 74
Study 15585750 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialogic reading
Number of subjects: 28
Study 15585750 — intervention group
Group type: COMPARATOR
Intervention: Typical reading
Number of subjects: 28
Study 15585750 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study 12897740 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (occupant education, insecticide bait placement, professional cleaning)
Number of subjects: 31
Study 12897740 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 31
Study 9460945 — intervention group
Group type: EXPERIMENTAL
Intervention: Triosite blocks
Number of subjects: 341